Abstract
Premenstrual dysphoric disorder (PMDD) is characterized by the recurrence of major psychiatric symptoms in the final week before the onset of menses, which severely impact womens quality of life. The etiology of PMDD, or more generally premenstrual syndrome (PMS) including subclinical forms, is not well understood and both biological and psychological models have been postulated. In the current manuscript we explore the role of emotion regulation ability for the emergence of premenstrual symptoms. Specifically, we were interested whether difficulties in emotion regulation in women with PMS/PMDD persisted as a trait across all cycle phases or were specific to the symptomatic premenstrual phase. We also explored for the first time, whether difficulties in emotion regulation already emerged during the high progesterone mid-luteal phase. 105 women aged 18 to 35 years completed a trait questionnaire on difficulties in emotion regulation, as well as two state measures of emotion regulation during three cycle phases (mid-follicular, mid-luteal, premenstrual). PMS/PMDD was prospectively confirmed across two menstrual cycles in 54 women, while the remaining 51 were assigned to the control group. Our results confirm previous findings that women with PMS/PMDD subjectively report more difficulties in emotion regulation on a trait scale. However, these difficulties were not confirmed in any of the state measures employed in the current study. Furthermore, difficulties in emotion regulation did not account for premenstrual symptom severity in a mediation analysis. This raises the question, whether difficulties in emotion regulation underly premenstrual symptoms or the perception of impaired emotion regulation arises as a consequence of untreated PMS/PMDD. Noteworthy, we were also able to demonstrate via Bayesian analyses, that mood worsening in the premenstrual phase is not a universal occurrence and absent in healthy controls. Taken together these findings highlight the importance of adequate diagnosis and treatment of PMDD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was in part funded by the European Research Council (850953) and the Austrian Science Fund (W1233).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the University of Salzburg gave ethical approval for this work (GZ 24/2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.